In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer.
about
Vasohibin‑2 promotes proliferation in human breast cancer cells via upregulation of fibroblast growth factor‑2 and growth/differentiation factor‑15 expressionROR1 expression correlated with poor clinical outcome in human ovarian cancerHighly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapyNew ways to successfully target tumor vasculature in ovarian cancer.Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment.Increased PTOV1 expression is related to poor prognosis in epithelial ovarian cancer.Vasohibin-2 is required for epithelial-mesenchymal transition of ovarian cancer cells by modulating transforming growth factor-β signaling.Delivery strategies and potential targets for siRNA in major cancer typesPrognostic values of 5-hmC, 5-mC and TET2 in epithelial ovarian cancer.Atelocollagen-mediated in vivo siRNA transfection in ovarian carcinoma is influenced by tumor site, siRNA target and administration route.Requisite role of vasohibin-2 in spontaneous gastric cancer formation and accumulation of cancer-associated fibroblasts.LAMP3 expression correlated with poor clinical outcome in human ovarian cancer.
P2860
Q33891210-A948840C-FBFF-486B-BA09-E3CA85D35801Q33942010-22C659AB-D4AC-4203-AF5C-B7F4D1886BBDQ35284618-C3560C3E-0E60-40C2-A506-FDFF49848E43Q35928220-1253455E-5AF4-4BAE-ADD1-8C95DE211194Q37713632-6F40A4F4-BFFD-4D4B-84CD-9E81E152A751Q37735605-D6B48814-609B-4C9D-B9B0-10472F6DD0F8Q38389964-0C55446C-031A-4DAD-9C85-709709C04A42Q38722425-8DD88AC2-6DE5-422A-A426-BA0151521309Q38853191-71D6821B-0CD4-4BED-AC2E-4ECA3CFD139EQ41134684-CB56CA4B-B20E-41E7-95BB-1F38B6FD0DDFQ45826092-0AC1F51C-DCC4-48E9-90A3-765815C9D8EDQ47103829-3D3B1F3B-B722-46DD-8E08-D28D72AE5498Q47813357-6989F102-CF64-4C8C-9526-EDCA270A3AEE
P2860
In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
In vivo delivery of siRNA targ ...... umor growth in ovarian cancer.
@en
In vivo delivery of siRNA targ ...... umor growth in ovarian cancer.
@nl
type
label
In vivo delivery of siRNA targ ...... umor growth in ovarian cancer.
@en
In vivo delivery of siRNA targ ...... umor growth in ovarian cancer.
@nl
prefLabel
In vivo delivery of siRNA targ ...... umor growth in ovarian cancer.
@en
In vivo delivery of siRNA targ ...... umor growth in ovarian cancer.
@nl
P2093
P2860
P356
P1433
P1476
In vivo delivery of siRNA targ ...... umor growth in ovarian cancer.
@en
P2093
Hiroyuki Fujiwara
Mitsuaki Suzuki
Shizuo Machida
Takahiro Koyanagi
Yasufumi Sato
Yasuhiro Suzuki
Yasushi Saga
Yuji Takei
P2860
P304
P356
10.1111/CAS.12297
P577
2013-11-08T00:00:00Z